Biomea Fusion: icovamenib boosts GLP-1 therapy insulin secretion; new oral GLP-1 RA BMF-650 shows early promise

Biomea Fusion, Inc.

Preclinical ex vivo human islet data show icovamenib combined with tirzepatide or semaglutide more than doubles glucose-stimulated insulin secretion under hyperglycemic conditions.
Phase II COVALENT-211 study combining icovamenib with a GLP-1-based therapy planned to begin in 2025.
New oral small-molecule GLP-1 RA candidate BMF-650 exhibited higher bioavailability, less variable PK; estimated human dose ~100 mg once daily.
In cynomolgus monkeys, BMF-650 improved glucose control and significantly suppressed appetite over a six-day dosing period.
BMF-650 also enhanced glucose-stimulated insulin secretion in human donor islets, supporting potential for diabetes and obesity treatment.

This headline and bullets were generated automatically by deepseek-v4-flash:cloud@v2 from the public filing. Read the source on SEC.gov before relying on any specific claim. Not investment advice. See methodology for how this pipeline works.